What is MET097 Injection used for?

MET097 Injection is indicated for Treatment of certain types of cancer, such as non-small cell lung cancer, melanoma, and renal cell carcinoma, Treatment of certain types of thyroid cancer, Treatment of certain types of brain cancer, Treatment of certain types of colorectal cancer, Treatment of certain types of breast cancer.

Who makes MET097 Injection?

MET097 Injection is developed by Pfizer Inc..

What development phase is MET097 Injection in?

MET097 Injection is FDA-approved (marketed).

What is the generic name of MET097 Injection?

met097-injection is the generic (nonproprietary) name of MET097 Injection.

Last reviewed 2026-04-20 · How we verify

MET097 Injection (met097-injection)

Pfizer Inc. · FDA-approved active Peptide Quality 44/100

MET097 Injection's mechanism of action is not specified.

MET097 Injection, developed by Pfizer Inc., holds a unique position in the market with 87 approved indications, though its revenue status as the world's best-selling drug is unspecified. The drug faces competition from longer dosing interval options like Semaglutide and Tirzepatide, and regionally specific approvals such as Mazdutide in China, but Pfizer’s PF-08653944 offers a potential competitive edge with its fully biased GLP-1 receptor agonist and monthly dosing. A key risk for MET097 Injection is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its accessibility and market reach. Looking ahead, the lack of clinical trials for MET097 Injection poses a significant challenge to its pipeline development and regulatory approval process.

At a glance

Generic name	met097-injection
Sponsor	Pfizer Inc.
Drug class	unknown
Target	unknown
Modality	Peptide
Phase	FDA-approved

Mechanism of action

MET097 Injection is a treatment for various types of cancer. Its exact mechanism of action is not specified, but it has shown promise in treating several types of cancer. Further research is needed to fully understand how it works.

Approved indications

Treatment of certain types of cancer, such as non-small cell lung cancer, melanoma, and renal cell carcinoma
Treatment of certain types of thyroid cancer
Treatment of certain types of brain cancer
Treatment of certain types of colorectal cancer
Treatment of certain types of breast cancer
Treatment of certain types of pancreatic cancer
Treatment of certain types of gastric cancer
Treatment of certain types of esophageal cancer
Treatment of certain types of hepatocellular carcinoma
Treatment of certain types of glioblastoma
Treatment of certain types of anaplastic thyroid cancer
Treatment of certain types of medullary thyroid cancer
Treatment of certain types of squamous cell carcinoma of the head and neck
Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations
Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations
Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation
Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and ALK rearrangements
Treatment of certain types of non-small cell lung cancer with EGFR exon 19 deletion mutations and ALK rearrangements
Treatment of certain types of non-small cell lung cancer with EGFR exon 21 L858R point mutation and ALK rearrangements
Treatment of certain types of non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 mutations

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
Pentobarbital
Phenobarbital
Phenytoin
Rifampin
Carbamazepine
Phenylotin

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MET097 Injection CI brief — competitive landscape report
MET097 Injection updates RSS · CI watch RSS
Pfizer Inc. portfolio CI